Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 4/2008

01-04-2008 | Gastrointestinal Oncology

Laparoscopic Gastrectomy: Feasibility, Safety and Efficacy

Author: Theodore Liakakos, MD

Published in: Annals of Surgical Oncology | Issue 4/2008

Login to get access

Excerpt

Screening programs, including access to endoscopy for the population in Japan and Korea, have substantially increased the rate of early-stage gastric cancer.1 Detecting gastric cancer and lymphoma at early stages (I and II) is the most powerful way to increase cure rates.2,3 With such an early diagnosis, most patients have a localized disease without micrometastases and can be cured with standardized, appropriate D2 surgery.1,4‐6 Efforts to improve the quality of life of these patients with expected long-term survival have resulted in the development of laparoscopic-assisted gastrectomy (LAG). This patient-friendly technique now attracts great attention and interest in the treatment of patients with gastric cancer as it can be associated with quicker return of gastrointestinal function, faster ambulation, and earlier discharge from hospital than open gastrectomy. However, there are several open questions regarding surgeon’s experience, operating time, morbidity, mortality, and recurrence.7 …
Literature
1.
2.
3.
Roukos DH, Hottenrott C, Encke A, Baltogiannis G, Casioumis D. Primary gastric lymphomas: a clinicopathologic study with literature review. Surg Oncol 1994;3:115–25PubMedCrossRef
4.
Siewert JR, Bottcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 1998;228:449–61PubMedCrossRef
5.
Roukos DH, Kappas AM. Targeting the optimal extent of lymph node dissection for gastric cancer. J Surg Oncol 2002;81:59–62PubMedCrossRef
6.
Kappas AM, Fatouros M, Roukos DH. Is it time to change surgical strategy for gastric cancer in the United States? Ann Surg Oncol 2004;11:727–30PubMedCrossRef
7.
Shehzad K, Mohiuddin K, Nizami S, et al. Current status of minimal access surgery for gastric cancer. Surg Oncol 2007;16:85–98. Epub 2007 Jun 7PubMedCrossRef
8.
Lee JH, Kim YW, Ryu KW. A Phase-II Clinical Trial of Laparoscopy-Assisted Distal Gastrectomy with D2 Lymph Node Dissection for Gastric Cancer Patients. Ann Surg Oncol 2007;14:3148–53PubMedCrossRef
9.
Roukos DH, Hottenrott C, Lorenz M, Koutsogiorgascouchell S. A critical-evaluation of effectivity of extended lymphadenectomy in patients with carcinoma of the stomach - an analysis of early results and long-term survival. J Cancer Res Clin 1990;116:307–13CrossRef
10.
Roukos DH. Extended lymphadenectomy in gastric cancer: when, for whom and why. Ann R Coll Surg Engl 1998;80:16–24PubMed
11.
Gervasoni JE, Sbayi S, Cady B. Role of Lymphadenectomy in Surgical Treatment of Solid Tumors: An Update on the Clinical Data. Ann Surg Oncol 2007; 14:2443–2462. DOI:10.1245/s10434-007–9360–5; PMID: 17597349 [PubMed - in process]
12.
Roukos DH. Extended (D2) lymph node dissection for gastric cancer: do patients benefit? Ann Surg Oncol 2000;7:253–5PubMedCrossRef
13.
Wu CW, Hsiung SA, Lo, et al. Nodal dissection for patients with gastric cancer: a randomised trial. Lancet Oncol 2006;7:309–15
14.
Roukos DH, Kappas AM. Perspectives in the treatment of gastric cancer. Nat Clin Pract Oncol 2005;2:98–107PubMedCrossRef
15.
Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725–30PubMedCrossRef
16.
Roukos DH. Adjuvant chemoradiotherapy in gastric cancer: wave goodbye to extensive surgery? Ann Surg Oncol 2002;9:220–1PubMed
17.
Cunningham D, Allum WH, Stenning SP, et. al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11–20.PubMedCrossRef
18.
Briasoulis E, Fatouros M, Roukos DH. Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use? Ann Surg Oncol 2007;14:2691–5.PubMedCrossRef
19.
Norton JA, Ham CM, Van Dam J, et al. CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg 2007;245:873–9PubMedCrossRef
20.
Chung DC, Yoon SS, Lauwers GY, Patel D. Case records of the Massachusetts General Hospital. Case 22-2007. A woman with a family history of gastric and breast cancer. N Engl J Med 2007;357:283–91PubMedCrossRef
21.
Kim JJ, Song KY, Chin HM, Kim W, Jeon HM, Park CH, Park SM. Totally laparoscopic gastrectomy with various types of intracorporeal anastomosis using laparoscopic linear staplers: preliminary experience. Surg Endosc 2007 Jun 26; DOI:10.1007/s00464-007–9446-y [Epub ahead of print]
22.
Roukos DH, Murray S, Briasoulis E. Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biol Ther 2007;6:308–12PubMed
23.
Roukos DH, Briasoulis E. Individualized preventive and therapeutic management of hereditary breast ovarian cancer. Nat Clin Pract Oncol 2007;4:578–90PubMedCrossRef
24.
Roukos DH, Kappas AM, Tsianos E. Role of surgery in the prophylaxis of hereditary cancer syndromes. Ann Surg Oncol 2002;9:607–9PubMedCrossRef
25.
Roukos DH, Agnanti NJ, Paraskevaidis E, Kappas AM. Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations. Ann Surg Oncol 2002;9:941–3PubMed
26.
Fatouros M, Baltoyiannis G, Roukos DH. The predominant role of surgery in the prevention and new trends in the surgical treatment of hereditary breast ovarian cancer. Ann Surg Oncol 2007 Oct 17 (DOI:10.1245/s10434-007–9612-4) [Epub ahead of print] PMID: 17940826
27.
Roukos DH, Kappas AM, Agnantis NJ. Perspectives and risks of breast-conservation therapy for breast cancer. Ann Surg Oncol 2003;10:718–21.PubMedCrossRef
28.
Fatouros M, Roukos DH, Arampatzis I, Sotiriadis A, Paraskevaidis E, Kappas AM. Factors increasing local recurrence in breast-conserving surgery. Expert Rev Anticancer Ther 2005;5:737–45.PubMedCrossRef
29.
Agnantis NJ, Paraskevaidis E, Roukos D. Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance. Ann Surg Oncol 2004;11:1030–4PubMedCrossRef
30.
Roukos DH. Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 2007;357:1555–6.PubMedCrossRef
Metadata
Title
Laparoscopic Gastrectomy: Feasibility, Safety and Efficacy
Author
Theodore Liakakos, MD
Publication date
01-04-2008
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 4/2008
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-007-9689-9

Other articles of this Issue 4/2008

Annals of Surgical Oncology 4/2008 Go to the issue

Gastrointestinal Oncology

Reasons for Explantation of Totally Implantable Access Ports: A Multivariate Analysis of 385 Consecutive Patients

Hepatic and Pancreatic Tumors

Prognostic Significance of CD44s Expression in Biliary Tract Cancers

Gastrointestinal Oncology

Advances in Laparoscopic Gastrectomy Expand Clinical Use

Laboratory Research

Messenger RNA Expression of Vascular Endothelial Growth Factor and Its Receptors in Primary Colorectal Cancer and Corresponding Liver Metastasis

Melanomas

Factors Predictive of Nonsentinel Lymph Node Involvement and Clinical Outcome in Melanoma Patients With Metastatic Sentinel Lymph Node

Gastrointestinal Oncology

Systemic Therapy for Hepatocellular Carcinoma: Cytotoxic Chemotherapy, Targeted Therapy and Immunotherapy